HEXAFLUORENIUM

US Previously Marketed

First approved in 1955

Details

Stereochemistry	ACHIRAL
Molecular Formula	C36H42N2
Molecular Weight	502.7321
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	2

SHOW SMILES / InChI

Structure Search

SMILES

C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C3=C1C=CC=C3)C4C5=C(C=CC=C5)C6=C4C=CC=C6

InChI

InChIKey=HDZAQYPYABGTCL-UHFFFAOYSA-N

InChI=1S/C36H42N2/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3/q+2

HIDE SMILES / InChI

Description
Sources: https://books.google.ru/books?id=cQkrDAAAQBAJ&pg=PA224&lpg=PA224&dq=HEXAFLUORENIUM+dosage&source=bl&ots=emH5xIW6_Z&sig=rxIXxG4jzMSsjPyY6oRmuvpf0IQ&hl=ru&sa=X&ved=0ahUKEwjI8_qpnKvUAhVCrRQKHWLPBZsQ6AEIOjAD#v=onepage&q=HEXAFLUORENIUM&f=false
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/948350

Hexafluorenium inhibits the enzyme cholinesterase in the plasms, but apparently not at the neuromuscular juntion. It also has some nondepolarizing activity (tubocurarine-like) at the postjunctional membrane. In man hexafluorenium potentiates the muscle relaxant effects of succinylcholine. As such, smaller doses of succinylcholine are required and fewer side effects like fasciculations, twitching and postoperative muscle pain are experienced.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cholinesterase 14 Target ID: P06276 Gene ID: 590.0 Gene Symbol: BCHE Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/948350	Inhibitor 8297		2.4 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Muscle contractions 5 Sources: http://journals.lww.com/anesthesia-analgesia/Citation/1955/03000/Mylaxen_R___Preliminary_Clinical_Evaluation_of_a.7.aspx https://www.jstage.jst.go.jp/article/kurumemedj1954/10/3/10_3_232/_pdf	Preventing		Approved 8429	MYLAXEN Approved Use Used as an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation and to prevent succinylcholine-induced muscle fasciculations.

Sourcing

Vendor/Aggregator	ID	URL
AAA Chemistry	AR-1B8335
ABI Chem	AC1L1GAN
ABI Chem	AC1Q1HVL
Angene	AGN-PC-0WALTL
AstaTech	A11703
BOC Sciences	317-52-2
Compound Cloud	3601
Compound Cloud	9434
KeyOrganics	AS-57449
Kingston Chemistry	KST-1A9368
MolPort	MolPort-006-111-202
MuseChem	R025024
NCI Plated 2007	19477
NovoSeek	3601
ZINC	ZINC000001566899	http://zinc15.docking.org/substances/ZINC000001566899
eMolecules	194047092
eNovation Chemicals	D584066
mcule	MCULE-6055456556
mcule	MCULE-8761766213

PubMed

Title	Date	PubMed
Pseudocholinesterase enzyme deficiency: a case series and review of the literature.	2009 Dec 4	20062665
Sertraline-induced pseudocholinesterase enzyme deficiency.	2010 Nov 16	21189834

Patents

Sample Use Guides

In Vivo Use Guide

Hexafluorenium has been employed in a dose of 0.4 mg/kg i.v. to prolong the relaxant effects of succinylcholine

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Name

Type

Language

HEXAFLUORENIUM

Common Name

English

HEXAFLURONIUM

Common Name

English

HEXAFLUORENIUM [VANDF]

Common Name

English

HEXAFLUORENIUM CATION

Common Name

English

HEXAMETHYLENEBIS(FLUOREN-9-YLDIMETHYLAMMONIUM)

Systematic Name

English

1,6-HEXANEDIAMINIUM, N,N'-DI-9H-FLUOREN-9-YL-N,N,N',N'-TETRAMETHYL-

Systematic Name

English

Hexafluronium [WHO-DD]

Common Name

English

HEXAFLUORENIUM ION

Common Name

English

Classification Tree Code System Code

WHO-ATC

M03AC05